BRPI0911469A2 - inibidores de gm-csf e il-17 para terapia - Google Patents

inibidores de gm-csf e il-17 para terapia

Info

Publication number
BRPI0911469A2
BRPI0911469A2 BRPI0911469A BRPI0911469A BRPI0911469A2 BR PI0911469 A2 BRPI0911469 A2 BR PI0911469A2 BR PI0911469 A BRPI0911469 A BR PI0911469A BR PI0911469 A BRPI0911469 A BR PI0911469A BR PI0911469 A2 BRPI0911469 A2 BR PI0911469A2
Authority
BR
Brazil
Prior art keywords
csf
inhibitors
therapy
Prior art date
Application number
BRPI0911469A
Other languages
English (en)
Inventor
Christine Plater-Zyberk
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BRPI0911469A2 publication Critical patent/BRPI0911469A2/pt
Publication of BRPI0911469A8 publication Critical patent/BRPI0911469A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
BRPI0911469A 2008-04-29 2009-04-28 Inibidores de gm-csf e il-17 para terapia BRPI0911469A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12588008P 2008-04-29 2008-04-29
PCT/EP2009/055129 WO2009133103A1 (en) 2008-04-29 2009-04-28 Inhibitors of gm-csf and il-17 for therapy

Publications (2)

Publication Number Publication Date
BRPI0911469A2 true BRPI0911469A2 (pt) 2016-04-26
BRPI0911469A8 BRPI0911469A8 (pt) 2017-12-05

Family

ID=40810025

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911469A BRPI0911469A8 (pt) 2008-04-29 2009-04-28 Inibidores de gm-csf e il-17 para terapia

Country Status (16)

Country Link
US (1) US9353180B2 (pt)
EP (1) EP2279001B1 (pt)
JP (1) JP5771140B2 (pt)
KR (2) KR20160117643A (pt)
CN (2) CN102014958A (pt)
AU (1) AU2009242088B2 (pt)
BR (1) BRPI0911469A8 (pt)
CA (1) CA2717987C (pt)
EA (1) EA024654B1 (pt)
ES (1) ES2557494T3 (pt)
IL (1) IL209028A (pt)
MX (1) MX2010011309A (pt)
NZ (1) NZ587865A (pt)
UA (1) UA102097C2 (pt)
WO (1) WO2009133103A1 (pt)
ZA (1) ZA201006353B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424898A4 (en) * 2009-04-30 2012-12-05 Univ Mcgill CONJUGATES OF GM-CSF AND INTERLEUKIN-21 AND USES THEREOF IN MODULATION OF IMMUNE RESPONSE AND TREATMENT OF CANCER
AU2012204574B2 (en) * 2011-01-04 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating age-related macular degeneration
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
WO2014068029A1 (en) * 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
WO2004042009A2 (en) * 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060177436A1 (en) * 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
BRPI0608281B8 (pt) * 2005-04-18 2021-05-25 Amgen Res Munich Gmbh anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF

Also Published As

Publication number Publication date
UA102097C2 (ru) 2013-06-10
IL209028A0 (en) 2011-01-31
BRPI0911469A8 (pt) 2017-12-05
NZ587865A (en) 2012-06-29
US20110104172A1 (en) 2011-05-05
KR101681331B1 (ko) 2016-12-01
JP5771140B2 (ja) 2015-08-26
CN104338136A (zh) 2015-02-11
AU2009242088B2 (en) 2014-08-21
ES2557494T3 (es) 2016-01-26
CA2717987A1 (en) 2009-11-05
CA2717987C (en) 2018-11-13
IL209028A (en) 2015-08-31
KR20100135937A (ko) 2010-12-27
EA201001496A1 (ru) 2011-06-30
EA024654B1 (ru) 2016-10-31
EP2279001A1 (en) 2011-02-02
JP2011518857A (ja) 2011-06-30
US9353180B2 (en) 2016-05-31
EP2279001B1 (en) 2015-09-30
WO2009133103A1 (en) 2009-11-05
AU2009242088A1 (en) 2009-11-05
KR20160117643A (ko) 2016-10-10
MX2010011309A (es) 2010-12-14
CN102014958A (zh) 2011-04-13
ZA201006353B (en) 2015-04-29

Similar Documents

Publication Publication Date Title
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0911469A2 (pt) inibidores de gm-csf e il-17 para terapia
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0907183A2 (pt) Método e entidade para encriptação simétrica probabilítica
CY2017016I1 (el) Αναστολεις πρωτεασωματος
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
HRP20160658T1 (hr) Novi pirolni inhibitori reduktaze s-nitrozoglutationa kao terapeutska sredstva
BRPI0907257A8 (pt) sistemas e métodos para estimulação elétrica terapêutica
BRPI0910668A2 (pt) inibidores de proteína quinases
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
PT2414517T (pt) Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
BRPI0918564A2 (pt) inibidores
PT2340042E (pt) Métodos e composições para o tratamento de cancro
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
BRPI0914683A2 (pt) dispositivo para terapia de campo magnético
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
DK2358710T3 (da) AKT- og P70-S6-kinaseinhibitorer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0822849A2 (pt) Aparelho para cirurgia oftalmológica
BR112013015107A2 (pt) métodos e dispositivos para usar álcool isoperílico
BRPI0907150A8 (pt) dispositivo e método para microelastografia
BRPI0924107A2 (pt) inibidores de hsp90 para tratamento terapêutico
BRPI0920681A2 (pt) inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
ITFI20070288A1 (it) Inibitori delle deacetilasi istoniche

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MICROMET AG (DE)

Free format text: A FIM DE ATENDER AS DUAS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 20120113072/RJ, DE 06/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA A SEGUNDA ALTERACAO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

Owner name: MICROMET AG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MICROMET GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: AMGEN RESEARCH (MUNICH) GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL